|
WO2021044430A1
|
|
Anti-fibrotic compounds and use thereof
|
|
WO2020261265A1
|
|
Nucleic acid agents modulating slamf6 isoforms
|
|
WO2020250232A1
|
|
Methods of generating oligodendrocytes
|
|
WO2020234888A1
|
|
Methods of culturing human pluripotent cells
|
|
WO2020174476A1
|
|
Targeted magnetic vehicles and method of using the same
|
|
WO2020121305A1
|
|
Markers of disease prognosis in multiple sclerosis
|
|
WO2020031182A1
|
|
Multi-lumen syringes for intraocular injections
|
|
WO2019220441A1
|
|
Compositions and methods for treating cancer resistant to an anti-cancer agent
|
|
WO2019207582A1
|
|
Use of cb2 inhibitors for lymphocyte recovery
|
|
EP3768273A1
|
|
Methods and synergic compositions for treating viral infections
|
|
US2021052523A1
|
|
Tumor suppressive micrornas for cancer therapy
|
|
EP3752252A1
|
|
Modulation of slamf6 splice variants for cancer therapy
|
|
US2019209274A1
|
|
Systems and methods of automated in-situ preparation for mounting of prefabricated custom dental prosthesis
|
|
WO2019043699A1
|
|
Devices, kits and methods for reducing and/or preventing intra-abdominal adhesions
|
|
US2020139161A1
|
|
Device system and method for trans-cranial focused ultrasound without hair shaving
|
|
WO2018235076A1
|
|
Method and system for predicting response to pharmacological treatment from eeg
|
|
WO2018229762A1
|
|
Fetal scalp blood sampler for assessment of wellbeing
|
|
WO2018207193A1
|
|
Radiolabeled compounds that target organic cation transporters and uses thereof in radioimaging
|
|
US2020017484A1
|
|
Compounds for the treatment of glycogen storage disorders
|
|
AU2018217992A1
|
|
Photoreceptor cells for the treatment of retinal diseases
|
